Share Prices & Company Research

Market News

20 Jan 2021 | 12:59

NICE approves Amryt's Myalepta for reimbursement in England and Wales

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Wednesday that the National Institute for Health and Care Excellence (NICE) has approved 'Myalepta', or metreleptin, for reimbursement in England and Wales. The AIM-traded firm said the reimbursement approval was for the use of Myalepta as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy in adults and children two years of age and above, and familial or acquired partial lipodystrophy in adults and children 12 years of age and above.

Myalepta received marketing authorisation from the European Medicines Agency in 2018.

"We are very excited to report NICE's approval of Myalepta which will now give all England and Wales based patients suffering from lipodystrophy the opportunity to access Myalepta," said chief executive officer Dr Joe Wiley.

"Today's news represents further progress in our efforts to grow the geographic reach of our commercial products in both existing and new territories."

At 1241 GMT, shares in Amryt Pharma were up 2.36% at 199.6p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.